423 results on '"de Jong, Marion"'
Search Results
2. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
3. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
4. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
5. Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11
6. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
7. Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma
8. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
9. Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
10. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands:Synthesis and Preclinical Profile
11. Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach
12. In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
13. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “Holy Gray” in radionuclide therapy
14. Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules
15. Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification
16. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands: Synthesis and Preclinical Profile
17. Breast Imaging with Radiolabeled Peptides
18. Intravenous and intratumoral injection of Pluronic P94: The effect of administration route on biodistribution and tumor retention
19. Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer
20. Call to arms: need for radiobiology in molecular radionuclide therapy
21. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer
22. Translational molecular imaging in exocrine pancreatic cancer
23. [212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
24. Breast cancer imaging using radiolabelled somatostatin analogues
25. 99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice
26. Correction to: Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma
27. Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
28. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer:final results of a GRAN-T-MTC Phase I clinical trial
29. [212Pb]Pb-eSOMA-01:A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
30. Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
31. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
32. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [ 111 In]In-Radioligands: Synthesis and Preclinical Profile.
33. Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
34. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands
35. In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
36. The new era of cancer immunotherapy: what can molecular imaging do to help?
37. Radiolabeling polymeric micelles for in vivo evaluation: a novel, fast, and facile method
38. Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
39. Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
40. Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation
41. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT
42. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
43. Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
44. [ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.
45. Highlights lecture EANM 2014: “Gimme gimme gimme those nuclear Super Troupers”
46. Biomarkers in preclinical cancer imaging
47. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
48. Peptide Receptor Radionuclide Therapy: Preclinical Findings
49. Modeling Early Radiation DNA Damage Occurring during 177Lu-DOTATATE Radionuclide Therapy
50. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.